Ms. Julia Becker reports

TEMPRAMED ANNOUNCES LIFE OFFERING UP TO C$8 MILLION TO ACCELERATE GLOBAL EXPANSION AND FULFILMENT OF FORECASTED DEMAND

Tempramed Technologies Ltd. intends to complete a non-brokered private placement offering pursuant to the listed issuer financing exemption (the LIFE offering) under Part 5A of National Instrument 45-106, Prospectus Exemptions, as amended.

Recent highlights:

• Record sales: July, 2026, sales were about $522,000 (U.S.), the best month in the company's history, and August was about $403,000 (U.S.), its second best; run-rate revenue of approximately $5.5-million (U.S.);
• Sales for the first eight months of 2026 were about $2.07-million (U.S.), already above the $1.8-million (U.S.) booked for all of 2025;
• Growing patent portfolio: four new global patents granted in 2026;
• Global distribution: 15 new and renewed distribution commercial relationships signed in 2026, including direct B2B (business-to-business) agreements with Humana, McKesson, Maccabi and Meuhedet;
• Signed agreements with disclosed dollar minimums with Saudi Arabi and Kuwait and a strong pipeline of future agreements;
• Saudi Arabia: five-year deal for a private label Vivi Cap, sold through Nahdi, Saudi Arabia's largest pharmacy chain (over 1,100 stores), with firm order for 10,000 units late 2026;
• Retail distribution network: includes Walgreens, Amazon and Target;
• Forecasted demand: 20,000 to 25,000 units through all channels in next 90 days with growing pipeline of demand into 2027.

The company intends to complete the LIFE offering through the issuance of up to 16 million units of the company at a price of 50 cents per unit for up to aggregate gross proceeds of $8-million. Each unit will consist of one common share of the company and one non-transferable common share purchase warrant, with each warrant entitling the holder thereof to acquire one common share at a price of $1 per common share for a period of 18 months following the closing date (as defined below).

The net proceeds from the LIFE offering are expected to be used toward accelerating global growth and fulfilment of increased demand, product development, including completion of the refrigerated version of Vivi Med and the multimedication Vivi Box and continued development of the Vivi Cap Smart application, marketing activities, and toward general working capital.

Subject to compliance with applicable regulatory requirements and in accordance with NI 45-106, the units sold pursuant to the LIFE offering will be offered to purchasers resident in all provinces and territories of Canada pursuant to the listed issuer financing exemption and in certain offshore jurisdictions pursuant to available prospectus or registration exemptions in accordance with applicable laws. Subject to the rules and policies of the CSE, the securities issued under the LIFE offering will not be subject to resale restrictions in accordance with applicable Canadian securities laws.

The offering document related to the LIFE offering can be accessed under the company's profile on SEDAR+ and on the company's website. Prospective investors should read this offering document before making an investment decision. It is expected that closing of the LIFE offering will take place on or about Nov. 13, 2026, or such other date(s) as may be determined by the company. The LIFE offering may close in one or more tranches. Closing of the LIFE offering is subject to certain conditions, including, but not limited to, the receipt of all necessary approvals, including the approval of the Canadian Securities Exchange.

The company may compensate certain eligible finders in connection with the LIFE offering and may pay a cash commission of up to 7 per cent of the gross proceeds raised from purchasers introduced by such finders and may issue finder shares equal to up to 7 per cent of the number of units sold to such purchasers.

About Tempramed Technologies Ltd.

Tempramed Technologies is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, FDA-registered (U.S. Food and Drug Administration) thermal insulation devices that work 24 hours a day, seven days a week without batteries or external power. With a product line already in market including Vivi Cap, Vivi Cap Smart, Vivi Epi and Vivi Med, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time. With operations in North America, Europe, and Asia, Tempramed will continue to expand globally, offering a solution for medication protection and adherence.

We seek Safe Harbor.